October 19, 2009 12:23 PM
- Text
Bayer's Legal Woes: 125 Suits Over Yaz; FDA Allegedly Not Told of Trasylol Study
(MoneyWatch) Bayer faces more than 125 lawsuits over its Yaz contraceptive and new cases are being filed around the country at a rate of up to up to six a day, according to Courthouse News Service.
The cases all claim the same thing: That the new progesterone ingredient that Bayer used for Yaz causes more dangerous blood clots to form than previous formulations. BNET noted in July that drospirenone allegedly causes a buildup of potassium that slows down the heart rate, allowing clots to form.
A new White Plains, N.Y., case alleges a slightly more detailed theory of causation involving dehydration:
The cases all claim the same thing: That the new progesterone ingredient that Bayer used for Yaz causes more dangerous blood clots to form than previous formulations. BNET noted in July that drospirenone allegedly causes a buildup of potassium that slows down the heart rate, allowing clots to form.A new White Plains, N.Y., case alleges a slightly more detailed theory of causation involving dehydration:
Drospirenone blocks the hormone aldosterone, and can cause dehydration from increased potassium secretion and increased absorption sodium and water.
Studies have reported that the resulting electrolyte imbalance can lead to potentially fatal hyperkalemia arrhythmia and deep-vein thrombosis ...Separately, even though Bayer removed anti-bleeding drug Trasylol from the market in 2007, new lawsuits keep arriving. Three were filed in Wisconsin recently. One alleges that Bayer failed to tell the FDA that a 67,000-patient study showed Trasylol increased the risks of renal failure, heart attack and stroke:
After a 19-member advisory panel studied the matter, it recommended to the FDA that Bayer's warnings on Trasylol did not need to be strengthened, the complaints say.
But just days after the panel's recommendation, a professor at Harvard's School of Public Health contacted the FDA about a 67,000 patient study he helped to perform at Bayer's request. The study confirmed that Trasylol increased the risk of renal failure, heart attack and stroke, the plaintiffs claim. In addition, it suggests that patients who receive Trasylol are at an increased risk of death, kidney failure and congestive heart failure.
Bayer knew of the study and its results, but failed to disclose the data to the FDA, according to the complaints.
- Previous items on Bayer and contraception:
- On Yaz, Bayer Believes "a Multiple of a Rare Event Is Still a Rare Event"
- BMJ: Ingredient in Bayer's Yaz Causes More Blood Clots Than Rivals
- Suits Claim Bayer's Yaz Caused 50 Deaths; Novel Theory of Blood Clot Causation
- Bayer's Trasylol Killed Too Many People; Lawsuits Arrive
Latest Now in MoneyWatch
- Freddie Mac: Mortgages inch higher but stay low
- Banks in $25B deal to settle foreclosure abuses
- Joe Coffee: Scaling up without selling your soul
- Greek agreement accomplishes nothing
- 401K plans: New rules make costs clearer
- Are women leaders selling themselves short?
- Ask the Experts: New 401(k) rules
- Mortgage lenders strike a deal
- $25B foreclosure-abuse settlement reached
- Wholesale inventories rose 1 percent in December
- States, Feds to announce new mortgage settlement
- Management changes at Ford
- Unemployment aid applications near a 4-year low
- PepsiCo's net rises; plans to cut 8,700 jobs
- Smartr: A brilliant contacts app for smartphones
- What happens if your insurance company fails?
- Student loan debt: The next financial disaster?
Latest CBS News Headlines
on Facebook
on CBS News
- Mortgage settlement nets $40M for DC homeowners
- NH to receive $43.6M in mortgage settlement
- Market cap, schmarket cap, Apple still gets no respect
- Report says Canada could support up to 9 NHL teams
on Facebook
- Adele opens up about vocal cord surgery
- Mo. teen gets life in prison for murder of 9-year-old girl
- "American Idol": Jim Carrey's daughter out, and then disaster
on CBS News






